The event showcased latest breakthroughs in minimally invasive surgery, organ-preservation strategies, and targeted therapies
The new capital is expected to fund the company through 2029
Multi-year CDMO partnership combines AI-led virtual development, precision chemistry and GMP manufacturing to accelerate five high-science APIs across regulated markets
Rs 66 lakh acquisition will support DNA engineering and novel cell-gene therapy alternatives to conventional chemotherapy
The company said the increase—up to 20%—takes effect immediately, or as current contracts allow
The agreement will combine Biocytogen’s cutting-edge fully human antibody discovery platform with Sihuan Pharmaceutical’s extensive drug development
The milestone moves the company closer to its previously announced $120 million US expansion, with groundbreaking slated for late 2026
The Taipei facility boasts 10 GMP API production lines, with a total reactor volume exceeding 350,000 liters
The new entity will operate with separate resources, funding, and operations, while BioNTech will contribute related rights and mRNA technologies to support its ambitious mission
The biotechnology company will tap into Catalent’s expertise in induced pluripotent stem cells and advanced cell-therapy manufacturing
Subscribe To Our Newsletter & Stay Updated
